Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
Carsten Hellmann
|
| gptkbp:country |
gptkb:Denmark
|
| gptkbp:founded |
1923
|
| gptkbp:founder |
Peter Barfod
|
| gptkbp:headquartersLocation |
gptkb:Hørsholm,_Denmark
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALK-Abelló
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:legalForm |
Aktieselskab
|
| gptkbp:numberOfEmployees |
~2,600
|
| gptkbp:parentCompany |
none
|
| gptkbp:products |
adrenaline auto-injectors
allergy drops allergy tablets allergy vaccines |
| gptkbp:publiclyTraded |
gptkb:Nasdaq_Copenhagen
|
| gptkbp:revenue |
4.5 billion DKK (2022)
|
| gptkbp:servesArea |
worldwide
|
| gptkbp:specializesIn |
allergy diagnostics
allergy immunotherapy |
| gptkbp:stockExchange |
gptkb:Copenhagen_Stock_Exchange
|
| gptkbp:stockSymbol |
ALK-B
|
| gptkbp:subsidiary |
ALK-Abelló Nordic A/S
Allergy Therapeutics (USA) Inc. |
| gptkbp:website |
https://www.alk.net/
|
| gptkbp:bfsParent |
gptkb:Lundbeck_Foundation
|
| gptkbp:bfsLayer |
6
|